Centessa Pharmaceuticals Limited (CNTA)
|Net Income (ttm)||-51.58M|
|Trading Day||July 30|
|Day's Range||20.26 - 21.15|
|52-Week Range||19.61 - 26.90|
If two heads are better than one, consider what 10 can accomplish. That's the thinking behind Centessa Pharmaceuticals ( CNTA , Financial), a company constructed from the merger of 10 small drug companies.
If two heads are better than one, consider what ten can accomplish.
CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an...
Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additiona...
CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, deve...
CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Centessa Announces Pricing of Initial Public Offering
Biotech Centessa Pharma hoping for $250M IPO to top January series A and fund initial drug development
Centessa Pharmaceuticals, with four clinical and a dozen preclinical programs, expects its initial public offering to be slightly over the $250 million raised in a January series A. The largest single r...
Centessa Pharmaceuticals Limited has filed to go public with an IPO on the NASDAQ.
Centessa Pharmaceuticals was conceived by combining the primary strengths of the asset-centric model with the benefits of diversification and scale typically attributed to traditional large R&D organizations. The asset-centric model refers to single-purpose companies which are focused on developing a single program or programs associated with a single biological pathway. We have implemented this reimagined approach to R&D by initially combining a curated portfolio of ten wholly-owned asset-centric companies, which we refer to as the Centessa Su... [Read more...]
|IPO Date |
May 28, 2021
Saurabh Saha, M.D., Ph.D.
|Stock Exchange |
|Ticker Symbol |
The average 12-month stock price forecast for CNTA is 38.00, which is an increase of 84.11% from the latest price.